Dr Stephen McDonough, UK medical director at GSK, looks at the changing relationship between industry and health professionals and how the company is adapting to society’s growing demand for greater transparency
A week is a long time in politics – particularly true of the last seven days. But what does Brexit mean for life sciences? What's next for the UK's pharma, medtech and digital health sectors?
In the UK there has of course been great debate on Brexit – each side fighting its cause and every sector obviously having an opinion on what it would mean if the country does or doesn’t leave the EU
Simon Tilley, head of pharmaceuticals, SAS UK and Ireland talks about how organisations can finalise a strategy for compliance with Identification of Medicinal Products (IDMP) standards and the opportunities that it can provide
George Freeman, British minister for life sciences has said that if Britain was to leave the EU, it would make the UK, Europe and the globe a “less secure place and hinder not help the process of global trade”
The O’Neill review into antimicrobial resistance (AMR) challenges governments, industry and the medical profession to get to grips with bacterial resistance to antibiotics, “one of the biggest health threats facing mankind”
Donald Trump has said that “$300 billion could be saved” by making Medicare, the US federal health insurance programme, negotiate drug prices with pharma companies
